Companies and Brands Mike Mozart / Flickr 24/7 Insights The most shocking recall on this list is the 1982 Tylenol recall.  Recalling the Galaxy Note 7 was a huge blow to Samsung’s brand.  Shockingly, only two companies listed here went bankrupt …

Sanofi announces completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic?E.?coli?(9-valent) ( …

Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, …

Dive Brief: Sanofi has agreed to work with Johnson & Johnson on what could be the first vaccine against a deadly strain of E. coli. J&J developed the vaccine, now in Phase 3 testing, to fight extraintestinal pathogenic E. coli, a leading cause of …

A potential first-in-class extraintestinal pathogenic E. coli (ExPEC) vaccine set to be jointly developed by Sanofi and Janssen, could help to abate a pathogen that is key in driving global antimicrobial resistance (AMR). Sanofi and Janssen Pharmaceuticals …

Check out what's clicking on FoxBusiness.com Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli. The logo of …

Breaking News To develop and commercialize Janssen's Phase 3 vaccine candidate for extraintestinal pathogenic E.coli (9-valent). 10.03.23 Sanofi has entered into an agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to …

Sanofi SA SNY struck a deal with Janssen Pharmaceuticals, a unit of Johnson & Johnson JNJ, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent). The vaccine is currently in Phase 3 E.mbrace trial designed …

Sanofi has reached an agreement to develop and commercialise an experimental vaccine candidate for extraintestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m …

(Bloomberg) -- Sanofi struck a deal to help fund and sell an experimental vaccine developed by Johnson & Johnson against an invasive form of the digestive pathogen E. coli.  Sanofi will pay J&J’s Janssen unit $175 million upfront, as well as …